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Abstract
Background: Xenobiotics are neurotoxins that dramatically alter the health of the child. In addition, an inefficient
detoxification system leads to oxidative stress, gut dysbiosis, and immune dysfunction. The consensus among
physicians who treat autism with a biomedical approach is that those on the spectrum are burdened with
oxidative stress and immune problems. In a trial to understand the role of detoxification in the etiology of autism,
selected parameters related to sulfur-dependent detoxification mechanisms in plasma of autistic children from
Saudi Arabia will be investigated compared to control subjects.
Methods: 20 males autistic children aged 3-15 years and 20 age and gender matching healthy children as control
group were included in this study. Levels of reduced glutathione (GSH), total (GSH+GSSG), glutathione status (GSH/
GSSG), glutathione reductase (GR), glutathione- s-transferase (GST), thioredoxin (Trx), thioredoxin reductase (TrxR)
and peroxidoxins (Prxs I and III) were determined.
Results: Reduced glutathione, total glutathione, GSH/GSSG and activity levels of GST were significantly lower, GR
shows non-significant differences, while, Trx, TrxR and both Prx I and III recorded a remarkably higher values in
autistics compared to control subjects.
Conclusion: The impaired glutathione status together with the elevated Trx and TrxR and the remarkable over
expression of both Prx I and Prx III, could be used as diagnostic biomarkers of autism.
Background
Autism spectrum disorders (ASDs) are prevalent neuro-
developmental disorders that, based on a recent survey,
affect not less than 1 in 150 children born [1]. Lastly, in
Saudi Arabia (population under 23 million) there were
42 500 confirmed cases of autism in 2002, and many
more cases remain undiagnosed [2]. ASD diagnoses are
characterized by impairments in social relatedness and
communication, repetitive behaviours’, abnormal move-
ment patterns, and sensory dysfunction [3]. Further,
common co-morbidity conditions often associated with
an ASD diagnosis include gastrointestinal disease and
dysbiosis [4], autoimmune disease [5], and mental retar-
dation [6].
Several lines of evidence support an association of oxi-
dative stress with ASD in at least some cases. First, there
is evidence of reduced endogenous antioxidant capacity.
Specifically, reduced enzymatic activities of glutathione
peroxidase (GPX) [6-8], superoxide dismutase (SOD)
[7,8] and catalase [9,10], and reduced levels of total glu-
tathione (GSH), GSH/GSSG and cysteine [11] have been
reported. Levels of exogenous antioxidants were also
reportedly reduced in autism, including vitamin C, vita-
min E and vitamin A in plasma, and zinc and selenium in
erythrocytes [12]. A second indicator of altered oxidative
stress in autism is derived from evidence of impaired
energy metabolism [13]. Magnetic resonance spectro-
scopic study of the brains of autistic individuals showed
reduced synthesis of ATP [14]. In addition, higher lactate
[13,15,16] and pyruvate [17], levels have been reported.
Third, there have been reports of improvement in certain
behaviours following antioxidant administration to indi-
viduals with autism. In double-blind, placebo-controlled
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improved autistic behaviour over baseline observations.
Likewise, children with autism, who had decreased blood
levels of the antioxidants GSH and cysteine as well as a
decreased GSH/GSSG ratio compared with controls, had
increases of these following a 3-week supplementation
with betaine and folinic acid [11]. Fourth, increased
excretion of oxidative stress biomarkers has been
reported in children with autism. Specifically, the excre-
tion of a F2 isoprostane, 8 isoprostaglandin F2a is
increased in children with au t i s ms p e c t r u md i s o r d e r s
[20]. This isoprostane is a product of nonenzymatic oxi-
dation of arachidonic acid and is widely recognized as a
reliable marker of lipid peroxidation [21]. Furthermore,
nitric oxide, a free radical that can block energy produc-
tion, was found to be increased in autism as compared to
age and sex-matched controls [8]. In addition, elevated
nitrite concentrations have been detected in individuals
with autism along with elevations of thiobarbituric acid
reactive substances and xanthine oxidase activity in red
cells [22]. Consistent with the increased oxidative stress
biomarkers, children with ASD were found to have
increased body burdens of environmental toxins that
may generate oxidative stress [23-26]. Taken together,
these lines of evidence suggest that it is likely that at least
some children with autism exhibit enhanced oxidative
stress. However, none of these observations suggest how
oxidative stress can lead to autism.
The formation of cross-links between the SH groups of
cysteine amino acids to form disulfide bridges is an
important process for maintaining the 3-dimensional
structure of many proteins and enzymes. A cysteine thiol
group is also the active site of some enzymes. Abnormally
elevated thiols may possibly affect protein synthesis or
enzyme function through disulfide bonding to the cystei-
nyl groups at structurally or enzymatically important
sites, or by acting upon existing disulfide bridges. Ele-
vated cysteine can interact with immunoglobulins and
components of the complement pathway to reduce the
clearance of immune complexes, a process which may be
important in autoimmune-related diseases [27].
Such strong evidence of the contribution of oxidative
stress in the aetiology of autism together with the high-
lighted role of the thiol redox couple in maintaining
normal structure and function of many enzymatic and
non-enzymatic antioxidant initiated our interest to mea-
sure glutathione and thioredoxin metabolism -related
parameters in an attempt to understand how oxidative
stress could lead to autism in a Saudi population.
Methods
Subjects and methods
The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki (Edinburgh, 2000).
All subjects enrolled in the study had written informed
consent provided by their parents and assented to partici-
pate if developmentally able. Subjects for this study were
enrolled through the ART Center (Autism Research &
Treatment Center) clinic. The ART Center clinic sample
population consisted of children diagnosed on the ASD.
The diagnosis of ASD was confirmed in all subjects using
the Autism Diagnostic Interview-Revised (ADI-R) and
the Autism Diagnostic Observation Schedule (ADOS)
and 3DI (Developmental, dimensional diagnostic inter-
view). The ages of all autistic children range between 3
and 16 years old. All were males, non verbal. Intelligence
quotient (IQ) for all autistic children was below 80. All
were simplex cases. All are negative for fragile × gene
study. The control group recruited from well baby clinic
at king Khaled University Hospital and they were 3-16
year old. All participating subjects were excluded from
the investigation if they had dismorphic features, tuber-
ous sclerosis, angleman syndrome, or other serious neu-
rological (e.g., seizures), psychiatric (e.g., bipolar
disorder) or known medical conditions. All participants
were screened via parental interview for current and past
physical illness. Children with known endocrine, cardio-
vascular, pulmonary, liver, kidney or other medical dis-
ease were excluded from the study.
Ethics approval and consent
This work was ethically approved by the ethical commit-
tee of King Khalid Hospital, King Saud University
(Approval number is 11/2890/IRB). A written consent
was obtained from the parents of each individual case,
according to the guidelines of the ethical committee.
Samples collection
After overnight fast, 10 ml blood samples were collected
from both groups in test tubes containing heparin as
anticoagulant. Centrifugation was done; plasma was
obtained and deep frozen (at -80°C) until analysis time.
Chemicals and kits
All chemicals and kits used in this study were of analyti-
cal grade, a product of Sigma (USA), Biovision, Randox,
or Northwest Company.
Biochemical assays
Measurement of glutathione status
Measurement of reduced GSH, total glutathione and
GSH/GSSG ratio were assayed based on the glutathione
recycling system by 5, 5’-Dithio-bis (2-nitrobenzoic acid)
(DTNB) and glutathione reductase.
Determination of glutathione reductase activity (GR)
GR was measured by following the reduction in the
absorbance as NADPH converted to NADP at 340 nm
during the reduction of GSSG to GSH [28].
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The GST activity was assessed using (Biovision, USA)
assay kit. Based upon that GST-catalysed reaction
between GSH and the GST substrate, CDNB (1-chloro-
2, 4-dinitrobenzene). The GST-catalyzed formation of
GS-DNB produces a dinitrophenyl thioether which can
be detected by spectrophotometer at 340 nm.
Determination of thioredoxin reductase activity
TR activity was measured using commercially available
kit (Biovision, USA) according to the following princi-
ple:In the assay TR catalyzes the reduction of 5, 5’-
dithiobis (2-nitrobenzoic) acid (DTNB) with NADPH to
5-thio-2-nitrobenzoic acid (TNB2-), which generate a
strong yellow color (lmax = 412 nm). Since in crude
biological samples other enzymes, such as glutathione
reductase and glutathione peroxidase, can also reduce
DTNB, therefore, TR specific inhibitor is utilized to
determine TR specific activity. Two assays were per-
formed: the first measurement is of the total DTNB
r e d u c t i o nb yt h es a m p l e ,a n dt h es e c o n do n ei st h e
DTNB reduction by the sample in the presence of the
T Rs p e c i f i ci n h i b i t o r .T h ed i f f e r e n c eb e t w e e nt h et w o
results is the DTNB reduction by TR.
Determination of Thioredoxin I level
The Thioredoxin 1 (Trx 1) was assessed based on a
sandwich Enzyme- Linked Immunosorbent Assay
(ELISA) (product of northwest company). The microti-
ter plate provided has been pre-coated with a
monoclonal antibody specific to human Trx1. This sta-
tionary phase antibody binds sample or standard Trx 1
while nonbound proteins are removed by washing. Next,
bound Trx 1 is tagged with a biotin-conjugated mono-
clonal antibody specific for Trx1 followed by Avidin
conjugated to Horseradish Peroxidase (HRP). Subse-
quent addition of TMB substrate solution causes blue
color (650 nm) development proportional to the amount
of Trx1 originally captured by the stationary phase
antibody.
Determination of Peroxiredoxin I and III levels
The Peroxiredoxin 1(Prx1) and III (Prx3) were assessed
based on a sandwich Enzyme- Linked Immunosorbent
Assay (ELISA) (product of northwest company) similar
to that used in thioredoxin level assay discussed pre-
viously with one exception. The microtiter plate pro-
vided has been pre-coated with a monoclonal antibody
specific to human Prx1 or Prx 3 instead of Trx
1antibody.
Results
Table 1 and figures 1A-I demonstrate the total glu-
tathione, GSSG and GSH/GSSG in plasma of control
and autistic children. It is clear from the table that these
parameters recorded significantly impaired levels in
autistic samples when compared to age - matching con-
trols. Figure 1A represents the distribution of total GSH
in autistic and control group. It could be easily observed
Table 1 Mean ± S.D of all the measured parameters, percentage changes of autistic values relative to controls, and
significant levels between both groups.
Parameter Group N Mean ± S.D. Percentage change P value
Total glutathione (μmol/L) Control 20 8.28 ± 1.03 100.00 0.001
Autistic 20 4.46 ± 0.33 53.85
Oxidized glutathione (GSSG) (μmol/L) Control 20 0.32 ± 0.06 100.00 0.001
Autistic 20 0.54 ± 0.17 170.84
GSH/GSSG Control 20 26.07 ± 5.03 100.00 0.001
Autistic 20 8.03 ± 2.46 30.79
Glutathione reductase(U/L) Control 20 60.19 ± 15.42 100.00 0.052
Autistic 20 70.25 ± 16.35 116.71
Glutathione S transferase (μmol/min/ml) Control 20 0.73 ± 0.37 100.00 0.002
Autistic 20 0.42 ± 0.18 57.48
Peroxiredoxin 1 (ng/ml) Control 20 20.25 ± 5.99 100.00 0.001
Autistic 20 40.75 ± 17.92 201.23
Peroxiredoxin 3 (ng/ml) Control 20 24.30 ± 2.69 100.00 0.001
Autistic 20 43.05 ± 5.86 177.16
Thioredoxin 1 (ng/ml) Control 20 44.71 ± 7.43 100.00 0.001
Autistic 20 74.70 ± 9.04 167.09
Thioredoxin reductase (mU/ml) Control 20 1.83 ± 0.52 100.00 0.001
Autistic 20 3.37 ± 1.22 184.15
Independent student’s t-test between the control and autistic groups and percentage change in total glutathione level, oxidised glutathione (GSSG), GSH/GSSG,
glutathione reductase, glutathione -S- transferase, peroxiredoxin 1, peroxiredoxin 3 level, thioredoxin 1, thioredoxin reductase (mU/ml).
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values in (μmole/L) lower than the minimum value
recorded in control group. Autistic children recorded a
remarkable percentage decrease (-46.15%) compared to
age-matching control. Moreover while GSSG shows
remarkable higher values in autistics, recording 70%
increase, GSH/GSSG ratio was significantly lower, with
percentage decrease of (-70%) relative to control. Distri-
bution of these two parameters confirmed their altered
values in most of the studied autistic subjects (Figure 1B
&1C).
The significant reduction in plasma glutathione s
transferase activity in autistic patients compared to con-
trol (-42.52%) is shown in the graphical distribution
demonstrated in Figure 1E. 10/20 of control subject
recorded value of 0.75 (μmol/min/ml) or higher com-
pared to 19/20 of autistic subjects that recorded lower
values.
Table 1 together with Figure 1F show an obvious sig-
nificant elevation on thioredoxin reductase activity in
autistic patients (84.15%) compared to age and sex
matching control. Results shows that 20/20 of control
subject record enzymatic activity equal to 3 (mU/ml) or
lower compared to only half of the autistic participants
recorded this values. Moreover, results represented in
table 1 and Figure 1G demonstrate the levels of thiore-
d o x i ni np l a s m ao fc o n t r o la n da u t i s t i cc h i l d r e n .I t
c o u l db ee a s i l yn o t i c e df r o mt h et a b l et h a tt h i sp a r a -
meter recorded significantly raised levels in autistic sam-
ples when compared to age - matching controls.
Graphical distribution of Trx in autistic and control
groups show that 20/20 of the autistic children have Trx
levels range between 59.93-89.7 ng/ml while only 1/20
of the control samples recorded values within this
range. Autistic children recorded a high percentage
increase (67.09%) compared to age-matching control.
Tables 1 and Figures 1H &I demonstrate the peroxire-
doxin I and III levels in control and autistic subjects. It
could be easily noticed that prx I and prx III levels are
significantly higher in autistic patients compared to con-
trol. Prx I shows almost 3 folds higher values with high
percentage increase (101.23%) compared to control. In
case of prx III levels the highest value recorded in con-
trol subjects was less than the lowest value recorded in
autistic patients with no observed overlapping between
the two groups.
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Figure 1 Normal distribution of the measured parameters in plasma of control and autistic patients.
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tions between all the measured parameters. It could be
easily noticed that most of the measured parameters are
either positively or negatively correlated with different
levels of significance. Only those which demonstrate the
most significant correlations between glutathione in one
hand and thioredoxin- related parameters in the other
hand are presented in Figure 3.
Table 3 and Figure 3 demonstrate the receiver operat-
ing characteristics of the measured parameters. Area
under the curve, specificity and sensitivity of the mea-
sured parameters are illustrated
Discussion
Clinical and preclinical investigations of the actions of
antioxidative defence systems in the brain suggest sev-
eral ways in which ongoing oxidative stress as a primary
phenomenon might impact the occurrence and severity
of autism [11]. Mitochondrial dysfunction, leaky blood
brain barrier, higher levels of circulating cytokines and
autoimmune response to brain antigen may be pro-
moted by oxidative generation of neoepitopes, which
occurs via oxidative alteration of neurodevelopmental
proteins [29-31].
All cellular functions are affected by the prevailing
redox status, and sulfur metabolism plays a central role
in maintaining a redox potential that is favorable for
homeostasis. In the present study, the significantly
decreased plasma total GSH levels (table 1 and Figure
1A) among the participants diagnosed with autism is of
concern. GSH is a tripeptide of cysteine, glycine, and glu-
tamate that is synthesized in every cell of the body. The
essential intracellular reducing environment is main-
tained by the high ratio of reduced GSH/GSSG [32]. The
Table 2 Pearson correlation test showing correlation significance differences between the different measured
parameters:
Parameters Pearson Correlation Sig.
Total glutathione ~GSSG -0.536 0.000 N
b
Total glutathione level ~ Glutathione reductase -0.339 0.032 N
b
Total glutathione ~Glutathione S Transferase 0.502 0.001 P
a
Total glutathione ~ Peroxiredoxin 1 -0.553 0.000 N
b
Total glutathione ~ peroxiredoxin 3 -0.861 0.000 N
b
Total glutathione ~ thioredoxin 1 -0.800 0.000 N
b
Total glutathione ~thioredoxin reductase -0.550 0.000 N
b
Total glutathione ~ GSH/GSSG 0.871 0.000 P
a
GSSG ~ glutathione S Transferase -0.436 0.005 N
b
GSSG ~ peroxiredoxin 3 0.543 0.000 P
a
GSSG ~ thioredoxin 1 0.602 0.000 P
a
GSSG ~ thioredoxin reductase 0.447 0.004 P
a
GSSG ~ GSH/GSSG -0.801 0.000 N
b
Glutathione reductase) ~ peroxiredoxin 1 0.464 0.003 P
a
Glutathione S transferase ~ peroxiredoxin 3 -0.364 0.021 N
b
Glutathione S Transferase ~ thioredoxin 1 -0.434 0.005 N
b
Glutathione S Transferase ~ thioredoxin reductase -0.494 0.001 N
b
Glutathione S Transferase ~ GSH/GSSG 0.513 0.001 P
a
Peroxiredoxin 1 ~ Peroxiredoxin 3 0.519 0.001 P
a
Peroxiredoxin 1 ~ thioredoxin 1 0.517 0.001 P
a
Peroxiredoxin 1 ~ thioredoxin reductase 0.446 0.004 P
a
Peroxiredoxin 1 ~ GSH/GSSG -0.525 0.001 N
b
Peroxiredoxin 3 ~ thioredoxin 1 0.873 0.000 P
a
Peroxiredoxin 3 ~ thioredoxin reductase 0.617 0.000 P
a
Peroxiredoxin 3 ~ GSH/GSSG -0.803 0.000 N
b
Thioredoxin 1 ~ thioredoxin reductase 0.615 0.000 P
a
Thioredoxin 1 ~ GSH/GSSG -0.779 0.000 N
b
Thioredoxin reductase ~ GSH/GSSG -0.558 0.000 N
b
a Positive Correlation.
b Negative Correlation.
Al-Yafee et al. BMC Neurology 2011, 11:139
http://www.biomedcentral.com/1471-2377/11/139
Page 5 of 9GSH redox equilibrium regulates a wide range of func-
tions that include nitrogen and oxygen free radical sca-
venger [33], protein redox status and enzyme activity
[34], cell membrane integrity and signal transduction
[35,36], transcription factor binding and gene expression
[37], phase II detoxification [38], and apoptosis [39]. The
observed depletion of total GSH could be supported
through considering the recent reports which also
demonstrate that, compared to controls, patients with
autism showed reduced levels of plasma total glutathione
[40,41]. Oxidative stress caused by GSH depletion may
also play a role in the increased male to female ratio
observed in autism. Because of lower levels of reduced
glutathione, mitochondria from males, when compared
to females, are more vulnerable to oxidative stress [42].
In animal studies, due to lower enzyme activity levels of
superoxide dismutase (SOD) and glutathione peroxidase
in males, oxidative damage to mitochondrial DNA is 4-
fold higher in males compared to females [43]. The
obtained higher GSSG levels as a reliable marker of intra-
cellular oxidative stress in autistics (table 1 and Figure
1B) could find a support in the previous work of James et
al., 2004 [12] who recorded 72% higher GSSG in children
with autism when compared to neurotypical children.
The unexpected, non-significant change in the activity
of glutathione reductase in autistic children when com-
pared to normal controls (table 1 and Figure 1D) could
be explained on the basis that under physiological con-
ditions, glutathione reductase activity is sufficient to
maintain an elevated reduced/oxidized glutathione ratio.
However, excessive intracellular oxidative stress, exceed-
ing the capacity of glutathione reductase will induce
export of GSSG to the plasma in an attempt to regain
intracellular redox homeostasis [44].
The significant reduction in plasma glutathione -S-
transferase in plasma of autistic patients compared to
Figure 2 Pearson’s correlations of the most significant positive and negative correlated variables listed in table 3.
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correlated to lack of substrate availability in autistic sub-
jects i.e. reduced glutathione( G S H )t h a tw a sp r e v i o u s l y
observed in autistic patients [11,40,41]. The recorded
reduction in this essential detoxifying enzyme could
explain the observed poor detoxification power in autis-
tic patients, such as in case of mercury or lead toxicity
[25,26,44]. The lower activity levels of glutathione-S-
transferase, reported in the present study is in good
agreement with the previous study done by Hung et al
[45] in which they proved that Glutathione-S-transferase
activity was reduced in autistic patients compared to
control. Moreover it could find a support in a genetic
study on this enzyme which revealed that M1 (GSTM1),
is reduced or absent in individuals carrying the
GSTM1*0 (null) allele, increasing their sensitivity to
xenobiotics [46] In addition, two recent studies have
reported an association between the null allele and aut-
ism suggesting that GST contributes to the risk of oxi-
dative stress and autism [46,47].
The key biological activities of Trx that are applicable
to human disease can be categorized as antioxidant,
growth promoting, anti-apoptotic and inflammation
modulating [48]. Beyond its protective role, the Txn sys-
tem is involved in various cellular processes, such as
cell-cell communication, transcriptional regulation, cell
signalling, and DNA synthesis [49]. Any particular biolo-
gical property of thioredoxin (Trx) is unlikely to be
either ‘good’ or ‘bad’ in human diseases [50]. Over
expression of TrxR as a major antioxidant enzyme,
recorded in the present study could support the hypoth-
esis stated that oxidative stress is linked with the etiol-
ogy of autism [11,47]. One of the most important roles
of the Trx/TrxR system is to maintain reduced redox
status and prevent oxidative stress. This function is
holding up mainly by the peroxiredoxin system. Recently
Drechsel and Patel [51] demonstrate that Trx/Prx is the
major contributing enzyme system to respiration-depen-
dent H2O2 removal in brain mitochondria, while GSH/
GPx and non-enzymatic systems show only minor con-
tributions. This pathway could be easily followed in Fig-
ure 4.
For all of that, in this study we also measured different
Prx levels to obtain their assumed role in autism. The
demonstrated over expression of both Prx I and Prx III
as biomarkers of oxidative stress in autistic patients
compared to age and gender-matching control subjects
(table 1 and Figure 1H &1I), could support their roles in
the pathology of autism. Besides their cytoprotective
antioxidant function, Prxs appeared to play an important
role in cell proliferation, differentiation, immune
response, protection of oxidant-sensitive proteins, regu-
lation of cellular H2O2 and control of apoptosis, pro-
cesses involving a redox signalling [52]. Prx3
overexpression alters the mitochondrial membrane
potential, reduces endogenous cellular H2O2 levels. The
results of Nonn et al [53] suggested that mitochondrial
Prx3 is an important regulator of H2O2 in the cell. They
reported that, at low physiological levels of H2O2,P r x 3
inhibits the growth-stimulating effects of H2O2, while at
Table 3 ROC analysis of the measured parameters showing area under the curve,cutoff values, sensitivity and
specificity.
Parameter Area under the curve Cutoff value Sensitivity % Specificity %
Total glutathione 1.000 9.320 100.0% 20.0%
Oxidised glutathione (GSSG) 0.919 0.380 80.0% 80.0%
GSH/GSSG 1.000 31.100 100.0% 20.0%
Glutathione reductase 0.650 75.620 30.0% 90.0%
Glutathione- S- transferase 0.803 1.100 100.0% 15.0%
Peroxiredoxin 1 0.915 26.240 90.0% 80.0%
Peroxiredoxin 3 1.000 26.990 100.0% 85.0%
Thioredoxin 1 0.993 52.140 100.0% 85.0%
Thioredoxin reductase 0.881 2.350 65.0% 85.0%
Figure 4 Proposed model of H2O2 removal in brain
mitochondria[51].
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Page 7 of 9higher levels of H2O2 generation; Prx3 protects cells
against apoptosis [54].
Based on this information, the recorded raised levels
of Trx, TrxR and Prxs of the present study could be
related to the previous work of Al-Gadani et al [11] in
which they proved that Saudi autistic children are under
H2O2 stress due to over expression of SOD and a
slightly lower activity of catalase.
The lack of satisfactory specificity values in glu-
tathione-related parameters could be supported through
considering the facts that glutathione system is known
to be altered in many chronic neurological disorders
[11,54-56].
Conclusion
The satisfactory high values of both sensitivity and spe-
cificity recorded by Trx, TrxR and Prxs could help to
s u g g e s tt h e ma sb i o m a r k e r sf or the diagnosis of autism
in Saudi population. Based on this study which con-
firmed the impaired antioxidant status in Saudi autistics,
early intervention through supplementation of perfect
and safe antioxidants as omega-3, carnosine, selenium
and others could be helpful because no doubt that autis-
tic children who undergo intensive intervention, be it
behavioural or developmental, do better than children
who don’t.
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